Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 12.11.2013 | EN | Official Journal of the European Union | C 326/8 |

---

Prior notification of a concentration

(Case COMP/M.7084 — Medtronic Vascular/Backston/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 326/06

|  |  |
| --- | --- |
| 1. | On 5 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004[(1)](#ntr1-C_2013326EN.01000801-E0001) by which the undertaking Medtronic Vascular Holdings (Ireland), controlled by Medtronic Inc. (‘Medtronic’, USA), and Backston Management Limited (Cyprus), ultimately controlled by Renova Investment Group Ltd (‘Renova Group’, Russian Federation), acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of LLC Stentex (‘Stentex’, Russian Federation) by way of purchase of shares. |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2. | The business activities of the undertakings concerned are:   |  |  | | --- | --- | | — | Medtronic is active globally in the development and licensing of intellectual property rights in connection with medical technology and medical devices, |  |  |  | | --- | --- | | — | Renova Group is a business group that consists of asset management and direct portfolio investment funds owning and managing assets in metals, mining, machine building, construction development, energy, telecommunications, etc. in Russia, Europe, South Africa and the US, |  |  |  | | --- | --- | | — | Stentex will manufacture and sell cardiovascular medical products (in particular coronary stents and their related delivery systems) in the Russian Federation and potentially in Belarus and Kazakhstan. | |

|  |  |
| --- | --- |
| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation[(2)](#ntr2-C_2013326EN.01000801-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7084 — Medtronic Vascular/Backston/JV, to the following address:   |  | | --- | | European Commission | | Directorate-General for Competition | | Merger Registry | | 1049 Bruxelles/Brussel | | BELGIQUE/BELGIË | |

---

[Top](#document1)